{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:52:40Z","timestamp":1778863960351,"version":"3.51.4"},"reference-count":125,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Oncol"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:p>Recent years have seen a dramatic change in the approach towards diagnosing and treating Multiple Myeloma. Newer and more target specific approach to treatment has prolonged the survival for patients with multiple myeloma. The proteasome inhibitors make an important class of anti-myeloma drugs that disrupts the proteolytic machinery of the tumor cells preferentially, enhancing their susceptibility to apoptosis. Bortezomib, in particular has shown significant clinical efficacy in myeloma treatment. It is the most commonly used proteasome inhibitor and has been tested to be effective in prolonging the overall survival in several trials. Its combinations with cyclophosphamide and dexamethasone are the treatment of choice for standard risk patients following the mSMART guidelines. The success with its lower dosage in elderly and its proven efficacious subcutaneous usage makes Bortezomib a useful agent for maximizing patient compliance and minimizing therapy related toxicity and costs. This review discusses several trials where Bortezomib has been used as a single\/combination agent for front-line treatment of multiple myeloma.<\/jats:p>","DOI":"10.4137\/cmo.s7764","type":"journal-article","created":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T16:32:12Z","timestamp":1362069132000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma"],"prefix":"10.4137","volume":"7","author":[{"given":"Utkarsh","family":"Painuly","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA."},{"name":"4th Department of Internal Medicine, University Hospital and Charles University Faculty of Medicine, Hradec Kr\u00e1lov\u00e9, Czech Republic."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"key":"bibr1-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"bibr2-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60221-X"},{"key":"bibr3-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"issue":"12","key":"bibr4-CMO.S7764","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","volume":"16","author":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.","year":"1998","journal-title":"J Clin Oncol."},{"key":"bibr5-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13782"},{"key":"bibr6-CMO.S7764","unstructured":"HowladerN., NooneA.M., KrapchoM., editors. SEER Cancer Statistics Review, 1975\u20132009 (Vintage 2009 Populations). NationalCancer Institute. Available at http:\/\/seer.cancer.gov\/csr\/1975_2009_pops09\/. Published Apr 2012. Updated Aug 20, 2012. Accessibility verified Jan 13, 2013."},{"key":"bibr7-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.291"},{"key":"bibr8-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"bibr9-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200312"},{"key":"bibr10-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070389"},{"issue":"7","key":"bibr11-CMO.S7764","first-page":"18","volume":"47","author":"Willard W.R.","year":"1978","journal-title":"J Med Assoc State Ala."},{"key":"bibr12-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"bibr13-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"bibr14-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-374249"},{"key":"bibr15-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1411"},{"key":"bibr16-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-040410"},{"key":"bibr17-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8435"},{"key":"bibr18-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0493"},{"key":"bibr19-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200501428"},{"key":"bibr20-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200501724"},{"key":"bibr21-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1038\/35056572"},{"key":"bibr22-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402417"},{"key":"bibr23-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.67.1.425"},{"key":"bibr24-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.7-1-9"},{"key":"bibr25-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1361"},{"key":"bibr26-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1159\/000468687"},{"key":"bibr27-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.12.8945"},{"issue":"11","key":"bibr28-CMO.S7764","first-page":"2615","volume":"59","author":"Adams J.","year":"1999","journal-title":"Cancer Res."},{"key":"bibr29-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.3.855"},{"key":"bibr30-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4400436"},{"key":"bibr31-CMO.S7764","doi-asserted-by":"crossref","first-page":"29860","DOI":"10.1016\/S0021-9258(18)43960-9","volume":"269","author":"Vinitsky CCA","year":"1994","journal-title":"J Biol Chem."},{"key":"bibr32-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.20.13437"},{"key":"bibr33-CMO.S7764","first-page":"279","volume":"31","author":"Adams J S.R.","year":"1996","journal-title":"Annu Rep Med Chem."},{"key":"bibr34-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1126\/science.7725107"},{"key":"bibr35-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1021\/bi952262x"},{"key":"bibr36-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(98)00029-8"},{"issue":"9","key":"bibr37-CMO.S7764","first-page":"3719","volume":"6","author":"Frankel A.","year":"2000","journal-title":"Clin Cancer Res."},{"key":"bibr38-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.2001.6194"},{"issue":"9","key":"bibr39-CMO.S7764","first-page":"3535","volume":"61","author":"Cusack J.C.","year":"2001","journal-title":"Cancer Res."},{"issue":"7","key":"bibr40-CMO.S7764","first-page":"3071","volume":"61","author":"Hideshima T.","year":"2001","journal-title":"Cancer Res."},{"key":"bibr41-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200360200"},{"key":"bibr42-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328302c7f4"},{"key":"bibr43-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.07.004"},{"key":"bibr44-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2151"},{"key":"bibr45-CMO.S7764","unstructured":"Millennium Pharmaceuticals Inc. (2008) VELCADE\u00ae (bortezomib) for Injection. Prescribing information. Cambridge, MA, USA; Issued Jun 2008, Rev 9 2009."},{"key":"bibr46-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"bibr47-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.06997.x"},{"key":"bibr48-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1283-3"},{"key":"bibr49-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13285"},{"key":"bibr50-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.005710"},{"key":"bibr51-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002956"},{"issue":"2","key":"bibr52-CMO.S7764","first-page":"273","volume":"21","author":"Leveque D.","year":"2007","journal-title":"In vivo."},{"key":"bibr53-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.9158"},{"issue":"9758","key":"bibr54-CMO.S7764","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo M.","year":"2010","journal-title":"Lancet."},{"key":"bibr55-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05540.x"},{"key":"bibr56-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"issue":"10","key":"bibr57-CMO.S7764","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos M.V.","year":"2010","journal-title":"Lancet Oncol."},{"key":"bibr58-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"bibr59-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07803.x"},{"key":"bibr60-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239046"},{"key":"bibr61-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.116"},{"key":"bibr62-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1853"},{"key":"bibr63-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.3087"},{"key":"bibr64-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.3323"},{"key":"bibr65-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019778"},{"key":"bibr66-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12106"},{"key":"bibr67-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0638"},{"key":"bibr68-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.08.017"},{"key":"bibr69-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-229658"},{"key":"bibr70-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05519.x"},{"key":"bibr71-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.5370"},{"key":"bibr72-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.606943"},{"issue":"2","key":"bibr73-CMO.S7764","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00277-011-1298-9","volume":"91","author":"Kim H.J.","year":"2012","journal-title":"Ann Hematol."},{"key":"bibr74-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"bibr75-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.26"},{"key":"bibr76-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0726-6"},{"key":"bibr77-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1420-7"},{"key":"bibr78-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31822043f6"},{"key":"bibr79-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.3109\/10428191003695660"},{"key":"bibr80-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11228"},{"key":"bibr81-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"bibr82-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08534.x"},{"key":"bibr83-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08703.x"},{"key":"bibr84-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408922"},{"key":"bibr85-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355081"},{"key":"bibr86-CMO.S7764","doi-asserted-by":"crossref","unstructured":"NiesvizkyR., FlinnI., RifkinR. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT Study. 2010. Available at http:\/\/myeloma.org\/pdfs\/ASH2011_Niesvizky_3599.pdf. Accessed Jan 13, 2013.","DOI":"10.1182\/blood.V118.21.478.478"},{"key":"bibr87-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.7172"},{"key":"bibr88-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.116"},{"key":"bibr89-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08949.x"},{"key":"bibr90-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8216"},{"key":"bibr91-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07981.x"},{"key":"bibr92-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00692.x"},{"key":"bibr93-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.07030"},{"key":"bibr94-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01599.x"},{"key":"bibr95-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0171"},{"key":"bibr96-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.310.310"},{"key":"bibr97-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.37.37"},{"key":"bibr98-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.12.580"},{"key":"bibr99-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1080\/10245330701214236"},{"key":"bibr100-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01771.x"},{"key":"bibr101-CMO.S7764","author":"Bortezomib.","year":"2010","journal-title":"Pubmed health."},{"key":"bibr102-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)61029-X"},{"key":"bibr103-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3684"},{"key":"bibr104-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M302559200"},{"key":"bibr105-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403109"},{"key":"bibr106-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2091"},{"key":"bibr107-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202445099"},{"key":"bibr108-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-078535"},{"key":"bibr109-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054221"},{"key":"bibr110-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-120576"},{"issue":"3","key":"bibr111-CMO.S7764","first-page":"1136","volume":"9","author":"Ma M.H.","year":"2003","journal-title":"Clin Cancer Res."},{"key":"bibr112-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1768"},{"key":"bibr113-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4322"},{"key":"bibr114-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210679"},{"key":"bibr115-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3531"},{"key":"bibr116-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902895780"},{"key":"bibr117-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503221102"},{"key":"bibr118-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210744"},{"key":"bibr119-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0676"},{"key":"bibr120-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2543"},{"key":"bibr121-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104"},{"key":"bibr122-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207170"},{"key":"bibr123-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1195"},{"key":"bibr124-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(01)00580-9"},{"key":"bibr125-CMO.S7764","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0433"}],"container-title":["Clinical Medicine Insights: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4137\/CMO.S7764","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.4137\/CMO.S7764","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4137\/CMO.S7764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:52:53Z","timestamp":1777614773000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.4137\/CMO.S7764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":125,"alternative-id":["10.4137\/CMO.S7764"],"URL":"https:\/\/doi.org\/10.4137\/cmo.s7764","relation":{},"ISSN":["1179-5549","1179-5549"],"issn-type":[{"value":"1179-5549","type":"print"},{"value":"1179-5549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]},"article-number":"CMO.S7764"}}